https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-832005-01-01 00:00:002019-02-15 08:50:23Immunotherapy and cancer vaccines in the management of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Methods Mol. Med. 2005;109:127-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Methods Mol. Med. 2005;109:127-362005-01-01 00:00:002019-02-15 08:51:03Dendritic cells in clinical trials for multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-622004-11-01 00:00:002021-11-15 15:38:39Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-82004-11-01 00:00:002019-02-15 08:50:25Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / J. Immunother. 2004 Nov-Dec;27(6):452-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / J. Immunother. 2004 Nov-Dec;27(6):452-92004-11-01 00:00:002019-02-15 08:46:58Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-812004-09-27 00:00:002020-06-23 09:41:00Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-09-01 / Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004 Sep;4(3):245-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-09-01 / Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004 Sep;4(3):245-512004-09-01 00:00:002019-02-15 08:53:34Dendritic cell-based immunotherapy in thyroid malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-08-15 / Clin. Cancer Res. 2004 Aug;10(16):5316-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-08-15 / Clin. Cancer Res. 2004 Aug;10(16):5316-262004-08-15 00:00:002019-02-15 08:47:00Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-08-05 / Proc. Natl. Acad. Sci. U.S.A. 2004 Oct;101 Suppl 2:14653-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-08-05 / Proc. Natl. Acad. Sci. U.S.A. 2004 Oct;101 Suppl 2:14653-62004-08-05 00:00:002019-02-15 08:48:24Therapeutic cancer vaccines: using unique antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-708
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-7082004-07-15 00:00:002004-07-15 00:00:00Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
